Genomic Health Gets KO'd By Next-Gen Long-Term Breast Cancer Assays
The new-generation of tests from Myriad and NanoString have outperformed Genomic Health's Oncotype Dx in predicting which breast cancer patients are at low-risk for a recurrence in five to ten years, and therefore do not need to be on extended endocrine therapy.
You may also be interested in...
This edition of device debuts highlights a wide variety of innovative devices introduced into commercial markets since the beginning of March, including a new stent for side-branch coronary interventions, an assay that identifies which breast-cancer patients do not need chemotherapy, a full ankle prosthesis, improvements to a negative-pressure wound therapy system, and a robotic system that helps paralyzed people learn to walk again.
The company stopped shipping Alaris in early 2020 after the FDA requested a new 510(k) for modifications and the device has been the subject of several recalls since then.
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.